BIO leader hits proposal for drug price regulation
The Cambridge-based chairman of the nation’s largest biotech organization is strongly opposing any federal controls in drug pricing if a prescription drug component is added to Medicare.
“It’s price controls or innovation; you can’t have both,” said Richard Pops, who recently was elected to head the board of directors of the Biotechnology Industry Organization (BIO), a Washington-based information and lobbying group. Pops is CEO of Alkermes Inc. in Cambridge.
Comments are closed.